| Market Capitalization (Millions $) |
20 |
| Shares
Outstanding (Millions) |
7 |
| Employees |
43 |
| Revenues (TTM) (Millions $) |
31 |
| Net Income (TTM) (Millions $) |
15 |
| Cash Flow (TTM) (Millions $) |
-20 |
| Capital Exp. (TTM) (Millions $) |
7 |
X4 Pharmaceuticals Inc
X4 Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development of innovative drugs to treat rare diseases. The company's primary focus is on the development of small molecule drugs that target chemokine receptors, which play a crucial role in various immune system functions and disease processes.
X4 Pharmaceuticals is known for its flagship drug candidate, mavorixafor, which is being developed for the treatment of several rare diseases, including WHIM syndrome, severe congenital neutropenia, and Waldenström macroglobulinemia. Mavorixafor has shown promising results in clinical trials, demonstrating its potential to address the underlying causes of these diseases and improve patient outcomes.
The company's approach involves harnessing the power of the immune system by selectively inhibiting specific chemokine receptors, with the aim of modulating immune cell trafficking and enhancing the body's immune response against diseases. X4 Pharmaceuticals has a strong pipeline of other drug candidates targeting various diseases, including cancer, primary immunodeficiency disorders, and advanced fibrosis.
Founded in 2015, X4 Pharmaceuticals is headquartered in Cambridge, Massachusetts, and has established collaborations with leading academic institutions, biotechnology companies, and research organizations to accelerate the development of its drug candidates. The company is committed to advancing innovative therapies to address significant unmet medical needs and improve the lives of patients with rare diseases.
Company Address: 61 North Beacon Street Boston 2134 MA
Company Phone Number: 529-8300 Stock Exchange / Ticker: NASDAQ XFOR
|
5.29% 
103.1 %